Picard Medical to Showcase Next-Gen Artificial Heart Data at ASAIO 2026
Event summary
- Picard Medical's SynCardia unit will present new in vivo data on the Emperor Total Artificial Heart at ASAIO 2026 on June 18.
- A second presentation will analyze patient outcomes using the SynCardia Total Artificial Heart on June 19.
- The Emperor platform is SynCardia's next-generation fully implantable motor-driven artificial heart.
- SynCardia has performed over 2,100 implants of its current artificial heart technology across 27 countries.
The big picture
Picard Medical's presentations at ASAIO 2026 highlight both its established leadership in artificial heart technology and its push into next-generation solutions. The company is positioning itself at the forefront of mechanical circulatory support innovation, with over 2,100 implants demonstrating real-world clinical impact. The Emperor platform represents a strategic bet on fully implantable motor-driven technology to expand treatment options for advanced heart failure patients.
What we're watching
- Regulatory Pathway
- Whether the Emperor platform can secure FDA approval as quickly as its predecessor.
- Market Adoption
- The pace at which next-generation artificial hearts gain acceptance among cardiologists.
- Competitive Positioning
- How Picard Medical differentiates itself in the growing mechanical circulatory support market.